Skip to main content

First Patient Enrolled in the Phase 3 ELUCIDATE Trial of Pafolacianine Sodium (formerly OTL38) in the Intraoperative Identification of Lung Cancer Lesions

First Patient Enrolled in the Phase 3 ELUCIDATE Trial of Pafolacianine Sodium (formerly OTL38) in the Intraoperative Identification of Lung Cancer Lesions

Author Information:

On Target Laboratories, Inc.


WEST LAFAYETTE, Ind., July 8, 2020 /PRNewswire/ -- On Target Laboratories, Inc., a privately-held biotechnology company developing fluorescent markers to target and illuminate cancer during surgery, has announced that it has enrolled the first patient in the ELUCIDATE Trial, a Phase 3 clinical trial evaluating the efficacy and safety of pafolacianine sodium (formerly OTL38) in the intraoperative detection of lung cancer lesions.

"This pivotal study is pioneering the use of fluorescence guidance to intraoperatively identify lung cancer in real-time," said Sunil Singhal, M.D., Vice Chair, Translational Research and the William Maul Measey Associate Professor in Surgical Research in the Perelman School of Medicine at the University of Pennsylvania and a member of Penn's Abramson Cancer Center and principal investigator of the study. "Using a fluorescent imaging marker with high affinity and specificity for lung cancer allows surgeons to more effectively remove all the malignant tissue and have greater confidence in a complete resection."

The Phase 3 study will assess the efficacy, safety, and tolerability of pafolacianine sodium in patients with lung cancer. This multi-center trial is expected to enroll up to 130 patients. Top-line data from the trial are expected in 2021.

"Treating our first patient in the ELUCIDATE Phase 3 Trial is an enormous achievement for On Target Laboratories," said Chris Barys, CEO of On Target Laboratories. "We believe this transformational technology should become the standard of care and look forward to bringing it to market so more lung cancer patients can benefit from the improved outcomes associated with more complete tumor resections." 

About Fluorescence-Guided Surgery

To date, there have been limited ways for surgeons to confidently assess the location and full extent of cancerous tissue while operating. On Target Laboratories' fluorescent markers are comprised of a near-infrared dye and a targeting molecule, or ligand, that binds to receptors overexpressed on cancer cells. These markers illuminate the cancerous lesions, lighting the way for the resection of malignant tissue and enabling surgeons to see and remove more diseased tissue.

On Target's first novel compound, pafolacianine sodium, targets folate receptors commonly found on many cancers, including lung and ovarian cancers. A small single dose of the compound is administered via intravenous infusion prior to surgery, allowing the surgeon to identify malignant tissue during the procedure using a near-infrared camera.

About On Target Laboratories, Inc.

On Target Laboratories discovers and develops fluorescent markers to target and illuminate cancer during surgery so it can be removed more completely. Their intraoperative molecular imaging technology, based on the pioneering work of Philip S. Low, PhD, reduces the uncertainty associated with finding and removing diseased tissue during medical procedures, empowering surgeons to provide a more accurate and complete surgical resection. Pafolacianine sodium, the Company's first product, is currently under development for use during surgery for ovarian and lung cancer and is not yet approved. For more information visit

SOURCE On Target Laboratories, Inc.

Related Links

Related Content

Read the IO Learning Interview with Dr. Philip Low about the Phase 2 trial results on pafolacianine sodium (OTL38) here.

Back to Top